	US 12,303,477 B2
	HIV treatment compositions and methods
Kayvan Niazi, Culver City, CA (US); Jeffrey Safrit, Culver City, CA (US); and John H. Lee, Culver City, CA (US)
Assigned to NantCell, Inc., Culver City, CA (US); and NantKwest, Inc., Dan Diego, CA (US)
Filed by NantCell, Inc., Culver City, CA (US)
Filed on Aug. 18, 2023, as Appl. No. 18/452,167.
Application 18/452,167 is a continuation of application No. 17/475,783, filed on Sep. 15, 2021, granted, now 11,786,577.
Application 17/475,783 is a continuation of application No. 16/443,560, filed on Jun. 17, 2019, granted, now 11,311,603.
Claims priority of provisional application 62/686,846, filed on Jun. 19, 2018.
Prior Publication US 2023/0398186 A1, Dec. 14, 2023
Int. Cl. A61K 31/167 (2006.01); A61K 31/192 (2006.01); A61K 31/215 (2006.01); A61K 31/4045 (2006.01); A61K 31/4406 (2006.01); A61K 31/506 (2006.01); A61K 35/17 (2025.01); A61K 38/20 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 39/395 (2006.01); A61K 40/11 (2025.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/46 (2025.01); C07K 14/735 (2006.01); C07K 16/10 (2006.01)

CPC A61K 31/167 (2013.01) [A61K 31/192 (2013.01); A61K 31/215 (2013.01); A61K 31/4045 (2013.01); A61K 31/4406 (2013.01); A61K 31/506 (2013.01); A61K 38/2086 (2013.01); A61K 39/12 (2013.01); A61K 40/11 (2025.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/46 (2025.01); C07K 14/70535 (2013.01); C07K 16/1003 (2023.08); C07K 16/1063 (2013.01)]

14 Claims

1. A method of treating an individual that carries latent human immunodeficiency virus (HIV) infected cells, the method comprising:

administering to the individual IL-15 or an enhanced immune stimulatory derivative thereof, and a broadly neutralizing anti-HIV antibody (bNAb).